Key facts
- Vertero Therapeutics’s last known valuation is $48.0M (Feb 2025).
- It has raised $111.2M; the latest was Later Stage VC ($19.8M) in Feb 2025.
- Notable investors include UTokyo Innovation Platform Company, ATEL Capital Group, Reimagined Ventures, OneVentures, Bayshore Global Management — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Vertero Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Vertero Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vertero Therapeutics
Developer of a new class of biotherapeutics designed for the treatment of neurological disorders. The company's products harness the gut-brain axis to develop a novel central nervous system that opposes diseases and disorders, enabling healthcare professionals with a new approach to diagnosing and improving the quality of life for people.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2016
- Employees
- 12
- Website
- vertero.com/
- Ownership
- Privately Held (backing)
Vertero Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vertero Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vertero Therapeutics in its N-PORT filings yet. We sweep new filings monthly.